JournalTOCs

Expert Opinion on Therapeutic Patents
Journal Prestige (SJR): 0.926

Citation Impact (citeScore): 3
Number of Followers: 12

Hybrid journal * Containing 1 Open Access article(s) in this issue *
ISSN (Print) 1354-3776 - ISSN (Online) 1744-7674
Published by Taylor and Francis

[2624 journals]

Recent development in the discovery of PARP inhibitors as anticancer
agents: a patent update (2016-2020)
- .
  Expert Opinion on Therapeutic Patents2021-03-12T08:32:48Z
  DOI: 10.1080/13543776.2021.1886275
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for
COVID-19
- .
  Expert Opinion on Therapeutic Patents2021-03-03T01:59:55Z
  DOI: 10.1080/13543776.2021.1880568
Tankyrase inhibitors as antitumor agents: a patent update (2013 –
2020)
- .
  Expert Opinion on Therapeutic Patents2021-03-02T08:13:46Z
  DOI: 10.1080/13543776.2021.1888929
Agonist of stimulator of interferon genes as antitumor agents: a patent
review (2008-2020)
- .
  Expert Opinion on Therapeutic Patents2021-03-02T04:37:30Z
  DOI: 10.1080/13543776.2021.1877660
Novel matrix metalloproteinase inhibitors: an updated patent review (2014
- 2020)
- .
  Expert Opinion on Therapeutic Patents2021-02-22T12:13:17Z
  DOI: 10.1080/13543776.2021.1881481
Pharmaceutical price regulation and its impact on drug innovation:
mitigating the trade-offs
- .
  Expert Opinion on Therapeutic Patents2021-02-10T11:38:06Z
  DOI: 10.1080/13543776.2021.1876029
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent
review (2010–present)
- .
  Expert Opinion on Therapeutic Patents2021-02-10T08:46:22Z
  DOI: 10.1080/13543776.2021.1866540
Novel ligands and modulators of triggering receptor expressed on myeloid
cells receptor family: 2015-2020 updates
- .
  Expert Opinion on Therapeutic Patents2021-02-08T10:19:06Z
  DOI: 10.1080/13543776.2021.1883587
Hypoxia-inducible factor (HIF) inhibitors: a patent survey
(2016–2020)
- .
  Expert Opinion on Therapeutic Patents2021-01-29T05:55:37Z
  DOI: 10.1080/13543776.2021.1874345
Inventive step assessment of top selling monoclonal antibodies in Brazil
- .
  Expert Opinion on Therapeutic Patents2021-01-19T07:56:15Z
  DOI: 10.1080/13543776.2021.1873955
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease
– a patent review (2016–present)
- .
  Expert Opinion on Therapeutic Patents2021-01-14T05:17:21Z
  DOI: 10.1080/13543776.2021.1874344
An updated patent review of autotaxin inhibitors (2017–present)
- .
  Expert Opinion on Therapeutic Patents2021-01-12T01:05:06Z
  DOI: 10.1080/13543776.2021.1867106
Therapeutic approaches targeting the neurotensin receptors
- .
  Expert Opinion on Therapeutic Patents2021-01-08T03:21:29Z
  DOI: 10.1080/13543776.2021.1866539
Monocyclic beta–lactams for therapeutic uses: a patent overview
(2010–2020)
- .
  Expert Opinion on Therapeutic Patents2021-01-07T08:47:29Z
  DOI: 10.1080/13543776.2021.1865919
Soluble guanylate cyclase stimulators and their potential use: a patent
review
Open Access Article
- .
  Expert Opinion on Therapeutic Patents2021-01-04T06:27:39Z
  DOI: 10.1080/13543776.2021.1866538
Repurposing drugs for the management of COVID-19
- .
  Expert Opinion on Therapeutic Patents2020-12-31T02:57:32Z
  DOI: 10.1080/13543776.2021.1861248
Multicomponent reactions (MCR) in medicinal chemistry: a patent review
(2010-2020)
- .
  Expert Opinion on Therapeutic Patents2020-12-29T02:05:31Z
  DOI: 10.1080/13543776.2021.1858797
Recent progress in the development of β2 adrenergic receptor agonists: a
patent review (2015-2020)
- .
  Expert Opinion on Therapeutic Patents2020-12-23T09:36:38Z
  DOI: 10.1080/13543776.2021.1865312
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the
treatment of non-small cell lung cancer: a patent review (2014-present)
- .
  Expert Opinion on Therapeutic Patents2020-12-14T06:43:29Z
  DOI: 10.1080/13543776.2021.1860210
Protease inhibitors targeting the main protease and papain-like protease
of coronaviruses
- .
  Expert Opinion on Therapeutic Patents2020-12-12T05:34:51Z
  DOI: 10.1080/13543776.2021.1857726